Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

NCT02662764 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-severe Acute Pain

Interventions

DRUG: Zalviso™ 15 mcg

Sponsor

Talphera, Inc